Business context and reporting period
The supplied filing is CryoLife, Inc.’s Form 10-Q for the quarter ended September 30, 2014—not a filing under the name Artivion, Inc. CryoLife develops and sells medical devices for cardiac and vascular applications and preserves and distributes human tissue for transplantation. The filing reports the third quarter and first nine months of 2014, compared with the same periods in 2013. Unless noted otherwise, amounts below are in millions of dollars.
Financial performance
| Metric | Q3 2014 | Q3 2013 | First 9 months 2014 | First 9 months 2013 |
|---|---|---|---|---|
| Revenue | $37.1 | $36.3 | $107.5 | $105.3 |
| Gross margin | $23.8; 64% | $23.3; 64% | $68.7; 64% | $68.1; 65% |
| Operating income | $3.0 | $4.6 | $6.9 | $10.7 |
| Net income | $2.3 | $3.2 | $5.5 | $7.1 |
| Diluted EPS | $0.08 | $0.11 | $0.19 | $0.25 |
| Operating cash flow | Not separately provided for the quarter | $3.3 | $11.3 |
- Quarterly revenue rose 2%; product revenue increased 8%, while preservation-services revenue declined 4%. For the nine-month period, revenue rose 2%, with products up 6% and preservation services down 2%.
- Q3 operating income fell 34% and nine-month operating income fell 35%, as operating expenses grew faster than revenue. General, administrative, and marketing expense increased 14% in Q3 and 7% year to date.
- Gross margin dollars increased modestly, but the nine-month gross margin rate slipped one percentage point. Net income declined despite a lower effective tax rate: about 21% in Q3 and 22% year to date, versus 32% and 31% in 2013. A $748,000 reversal of uncertain tax liabilities and tax expense contributed to the 2014 tax benefit.
- Cash and cash equivalents were $29.8 million at September 30, down from $37.6 million at December 31, 2013; an additional $5.0 million was restricted under the credit agreement. Working capital was $82.6 million, with a 5:1 current ratio.
- No borrowings were outstanding under the $20 million revolving credit facility; the full amount was available. The facility was extended to September 26, 2019. The company reported compliance with its covenants. Total liabilities were $28.3 million; the filing does not present a separate total-debt figure beyond the disclosed facility balance and other liabilities.
- Nine-month cash uses included $4.8 million for investing, $6.3 million for financing, $4.6 million of share repurchases, and $2.5 million of dividends. Capital expenditures were $3.2 million.
Material changes versus the prior comparable period
- BioGlue and BioFoam revenue rose 6% in both Q3 and the nine-month period. HeRO Graft revenue increased 45% in Q3 and 31% year to date; PerClot revenue increased 13% and 14%, respectively.
- Preservation revenue weakened amid reduced tissue availability following voluntary distribution restrictions connected to the company’s FDA compliance response. Vascular tissue revenue was down 6% in Q3 and 4% year to date; cardiac tissue revenue was down 3% in Q3 and slightly lower year to date.
- Product costs rose 18% in Q3 and 13% year to date, partly because of higher HeRO manufacturing costs associated with a facility transfer and lower throughput. Preservation processing costs per unit also increased.
- Operating cash flow fell to $3.3 million from $11.3 million, reflecting lower earnings and greater working-capital needs, including increases in inventories, deferred preservation costs, and prepaid expenses.
- Cash and cash equivalents declined by $7.8 million during the first nine months, compared with a $4.7 million increase in the comparable 2013 period. The company repurchased approximately 488,000 shares for $4.6 million during the period.
Outlook, commentary, risks, and unusual items
- Management expected Q4 2014 HeRO Graft revenue to increase year over year; cardiac preservation revenue to be comparable to or slightly above the prior-year quarter; and vascular preservation revenue to decline. It also expected higher Q4 administrative and marketing expense. Management expected research and development spending to increase materially in 2015, particularly for PerClot clinical trials.
- The company expected the higher per-unit cost of tissue processing to continue through the end of 2014 and into 2015. It stated that cash and operating resources should meet operational liquidity needs for at least 12 months, while noting expected spending on clinical trials, litigation, ProCol, dividends, repurchases, and business development.
- FDA inspection observations included design and process validation, environmental monitoring, product controls, corrective actions, and training. The company was communicating with the FDA and expected compliance efforts and related costs to continue at least through 2014. Further FDA action, including a recall or manufacturing hold, could materially affect results.
- An FDA advisory committee recommended classifying certain heart valves, including CryoValve SGPV, as Class III. If reclassified, the company anticipated needing to pursue premarket approval; cost, delay, or failure to obtain approval could materially affect tissue revenue.
- Bard and subsidiaries counterclaimed for patent infringement concerning PerClot and sought a preliminary injunction against U.S. marketing and sales. A hearing was scheduled for January 23, 2015. Management expected the litigation to be protracted and its costs in late 2014 and 2015 to be material.
- CryoLife held a $2.0 million secured loan receivable from ValveXchange. ValveXchange’s liquidity was described as critical; without additional funding, it might cease operations in Q4 2014, potentially impairing repayment.
- Other notable items: CryoLife began limited ProCol distribution under an exclusive worldwide distribution agreement and had paid Hancock Jaffe $1.7 million by quarter-end. In October 2014, it received a $530,000 contingent payment from the Medafor sale, to be recognized in Q4. The company also signed an office lease expected to begin in February 2015, with approximately $4.4 million of payments over the initial term.
Important facts for investors to verify
- Confirm the issuer identity: the supplied 10-Q is for CryoLife, Inc.; the request metadata names Artivion, Inc.
- Track FDA responses and any further restrictions, and determine the implications and timing of possible Class III reclassification and premarket approval for CryoValve SGPV.
- Monitor the Bard patent case, including the preliminary-injunction hearing and potential limits on PerClot sales, royalties, damages, or legal expense.
- Assess whether tissue availability and processing throughput recover, and whether management’s Q4 revenue expectations and cost assumptions are achieved.
- Review cash conversion and working-capital trends, the restricted $5.0 million, credit-facility covenant headroom, and the funding demands of trials, litigation, dividends, repurchases, and business development.
- Evaluate collectability of the ValveXchange loan and the value of its collateral, as well as the remaining contingent payments and milestones tied to Hemosphere and Medafor.